Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
暂无分享,去创建一个
R. Bernards | J. Engelman | A. Bardelli | J. Schellens | J. Tabernero | M. Buscarino | F. Di Nicolantonio | M. Linnebacher | E. Valtorta | G. Siravegna | A. Sartore-Bianchi | M. Gallicchio | Valentina Boscaro | S. Siena | M. Truini | L. Barault | G. Crisafulli | A. Bartolini | A. Cassingena | R. Corcoran | G. Corti | S. Arena | D. Oddo | R. van Geel | Carlotta Cancelliere | J. Grasselli | Jason Godfrey | Genny Filiciotto | E. Élez | E. Sennott | Giulia Marzolla | Giovanni Crisafulli | R. V. van Geel
[1] M. Bergo,et al. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF , 2016, Oncogene.
[2] Gang Li,et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.
[3] T. Greten,et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer , 2016, Investigational New Drugs.
[4] C. Atreya,et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Gibbs,et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[7] Beatriz Bellosillo,et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.
[8] S. Jaeger,et al. LBA-08Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer , 2015 .
[9] C. Atreya,et al. LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) , 2015 .
[10] Nikhil Wagle,et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. , 2015, Cancer discovery.
[11] J. Larkin,et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.
[12] C. Curtis,et al. A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.
[13] M. Salido,et al. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer , 2015, Clinical Cancer Research.
[14] P. Poulikakos,et al. Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.
[15] L. Garraway,et al. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. , 2014, Cancer research.
[16] K. Flaherty,et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[18] A. Bardelli,et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.
[19] K. Bachman,et al. Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models. , 2014 .
[20] J. Blay,et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). , 2014 .
[21] F. Meric-Bernstam,et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. , 2014 .
[22] R. Bernards,et al. Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the {alpha}-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. , 2014 .
[23] R. Bernards,et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). , 2014 .
[24] G. Pupo,et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma , 2014, Molecular oncology.
[25] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[26] A. Bardelli,et al. Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.
[27] G. Batist,et al. Use of statins and the risk of death in patients with prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.
[29] Shuxia Zhao,et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.
[30] Michael A. Davies,et al. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents , 2012, Clinical Cancer Research.
[31] Levi A Garraway,et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. , 2012, Cancer discovery.
[32] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[33] Wei Zhou,et al. ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors , 2012, Molecular Cancer Therapeutics.
[34] Mari Mino-Kenudson,et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.
[35] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[36] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[37] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[38] R. Jorissen,et al. Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation , 2011, International journal of cancer.
[39] P. Edwards,et al. Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.
[40] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[41] A. Iafrate,et al. BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation , 2010, Science Signaling.
[42] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[43] Suzie K. Hight,et al. Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. , 2010, Gastroenterology.
[44] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[45] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[46] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] N. Hanna,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .
[48] K. Fransén,et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. , 2003, Carcinogenesis.
[49] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[50] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[51] L. Naldini,et al. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy , 2000, The journal of gene medicine.